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Abstract
Background: Liraglutide is one of the glucagon-like peptide-1 analogs; there are only a few reports of liraglutide
being used for the treatment of insulin allergy. Furthermore, anti-insulin immunoglobulin G antibodies are
occasionally detected in patients with diabetes. Hence, we report a case in which switching to liraglutide therapy
ameliorated both the symptoms of insulin allergy with hypereosinophilia and the characteristics of insulin
antibodies in a patient with type 2 diabetes mellitus.
Case presentation: We present the case of a 70-year-old Japanese man with type 2 diabetes who developed
insulin allergy with hypereosinophilia. Anti-insulin antibodies, high glycated hemoglobin levels (approximately 12
%), and high serum insulin levels were detected. Because a change in his insulin treatment was inefficient,
treatment with liraglutide to protect residual insulin secretion was started, resulting in improvements in his insulin
allergy, serum glycated hemoglobin, insulin, and eosinophil levels. Scatchard plots revealed decreased binding
capacity and increased affinity constant for high affinity sites of anti-insulin antibodies.
Conclusions: Liraglutide might be useful for treating insulin allergy and anti-insulin antibodies in patients with type
2 diabetes.
Keywords: Liraglutide, Insulin allergy, Human insulin-specific immunoglobulin E, Hypereosinophilia, Anti-insulin
immunoglobulin G antibodies
Background
Insulin allergy is an important adverse effect of insulin
treatment in patients with diabetes. Ghazavi and Johnston
recently reported that the prevalence of allergic reactions
to insulin products is approximately 2 % at present [1].
Although the frequency of insulin allergy is low, the symp-
toms vary, ranging from local injection site reactions to
complete anaphylactic reactions [2, 3]. Given that ana-
phylactic reactions are occasionally life-threatening,
clinicians must act quickly and appropriately when
allergy is suspected.
Glucagon-like peptide-1 (GLP-1) analogs have recently
been introduced worldwide as a therapeutic option for
the treatment of type 2 diabetes. Liraglutide is one such
analog that improves blood glucose control by directly
affecting both insulin and glucagon secretion in the pan-
creas [4]. However, there are only a few reports of lira-
glutide being used for the treatment of insulin allergy,
and its effectiveness remains to be completely elucidated
in this context [5, 6]. Furthermore, anti-insulin immuno-
globulin G (IgG) antibodies [5, 7, 8] and anti-insulin
receptor antibodies [5, 9] are occasionally detected in
patients with diabetes who have brittle glycemic control
or severe insulin resistance. The effectiveness of liraglu-
tide remains unclear in these cases.
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We report a case in which switching to liraglutide ther-
apy ameliorated both the symptoms of insulin allergy with
hypereosinophilia and the characteristics of insulin anti-
bodies in patients with type 2 diabetes mellitus.
Case presentation
History leading to admission
Our patient is a 70-year-old Japanese man with diabetes.
He was admitted to our hospital 4.5 years ago for further
investigation and treatment of recent-onset insulin
allergy. He had a 30-year history of type 2 diabetes melli-
tus and an approximately 6-year history of insulin injec-
tion administration, with an average glycated hemoglobin
(HbA1c) level of 7.0 %. He reported a past history of myo-
cardial infarction, hypertension, and dyslipidemia and had
undergone coronary artery bypass grafting at 68 years.
During that surgery, intravenous protamine sulfate was
administrated, which induced anaphylaxis.
At that time, 4.5 years prior to the current presenta-
tion, he was receiving 100 mg/day aspirin, 100 mg/day
clopidogrel, 100 mg/day imidapril, 20 mg/day isosorbide
mononitrate, 5 mg/day nicorandil, and 10 mg/day prava-
statin, and these had been stable for more than 3 years.
In addition, he was being treated with 20 U/day insulin
lispro and 8 U/day insulin glargine, which had also been
unchanged for approximately 3 years. Finally, he had
been receiving 0.9 mg/day voglibose to supplement his
insulin therapy for approximately 5 years.
Approximately 5 months before his current presenta-
tion, he reported that he had started to develop wheals
with redness and itching at the injection site, which oc-
curred immediately after injecting insulin. Of note, these
symptoms only occurred following the use of insulin lis-
pro and not after insulin glargine. Over the subsequent
months, part of the surface of the wheals had hardened
and further investigation was performed. Two months
before his current admission, blood samples were taken
that revealed high serum levels of human insulin-
specific immunoglobulin E (IgE; 4.21 U/mL; normal
range <0.35 U/mL), hypereosinophilia (total white blood
cell count, 6000/μL; total eosinophil granulocyte count,
780; percentage, 13 %), and a high level of total IgE (403
IU/mL; normal range <173 IU/mL). A pathology sample
was taken 2 months before his admission, which re-
vealed eosinophilic infiltration in the hardened part of
the injection site (Fig. 1). Therefore, just before admis-
sion, he was diagnosed with insulin allergy and was
switched from insulin lispro plus glargine to insulin
aspart plus glargine.
Admission for further investigation
He was admitted to our hospital for treatment of his poor
glycemic control and to evaluate his residual ability of
insulin secretion. On admission, his physical examination
was largely unremarkable (height, 157.1 cm; body weight,
53.0 kg; body mass index, 21.5 kg/m2; body temperature,
36.5 °C; blood pressure, 104/62 mmHg; and pulse, 75
beats/minute, regular), although there was induration with
slight redness of his abdomen. His laboratory data at that
time are shown in Table 1. Of note, his fasting plasma glu-
cose level was 346 mg/dL, and his HbA1c level was 12.3
%. In addition, we detected high serum insulin, anti-
insulin IgG antibody, and anti-insulin receptor antibody
levels. Although there were no further symptoms of local
allergy (wheals, redness, and itching) after injecting with
insulin aspart, his postprandial hyperglycemia continued
at approximately 350 mg/dL. Therefore, he was switched
to insulin glulisine (24 U/day) plus glargine (22 U/day) after
admission. On day 17 of admission, his 24-hour blood glu-
cose profile was 88, 241, 241, 295, 297, and 292 mg/dL at
7:30 a.m., 10:00 a.m., 11:30 a.m., 2:00 p.m., 5:30 p.m., and
8:00 p.m., respectively, with an energy intake of 1600 kcal.
On days 18 and 19, his urinary excretion of C-peptide was
42.8 to 51.5 μg/day (normal range 40 to 100 μg/day). On
day 19, a glucagon stimulation test was performed, and his
Fig. 1 Pathological findings of insulin injection site. Specimen
obtained from the injection site of a 70-year-old man with
diabetes. Hematoxylin–eosin staining showing predominant
infiltration of eosinophils and the simultaneous infiltration of
lymphocytic cells in the subcutaneous tissue. a Low-power
micrograph 40×. b High-power micrograph 200×
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serum C-peptide response ranged from 3.2 to 3.6 ng/mL
(Table 2). On day 22, although his high glucose levels per-
sisted, he was discharged because we had confirmed his
ability to secrete insulin. Although his hypereosinophilia
was not resolved before his discharge, he had no further al-
lergic symptoms (wheals, redness, and itchiness) at the in-
jection site for glulisine, and the area of induration had
almost disappeared.
Progress since discharge and the introduction of
liraglutide
Figure 2 summarizes his clinical course before and after the
introduction of liraglutide. After discharge, although gluli-
sine and glargine were continued, his glycemic control
worsened, with fasting and postprandial hyperglycemia
levels of approximately 200 and 300 mg/dL, respectively,
and high serum insulin levels persisted (Fig. 2). Therefore, 2
months after his admission, we added 0.3 mg liraglutide,
discontinued the insulin glulisine, and added 2 mg/day
glimepiride and 500 mg/day metformin to decrease his
total insulin requirements. However, he also started to de-
velop intermittent induration at the site of insulin glargine
injection, and although there was no evidence of wheals or
redness, his hypereosinophilia persisted. Based on these
findings, we reduced the dose of glargine (32→22→26→10
U/day) and increased the dose of liraglutide (0.3→0.6→0.9
mg/day; Fig. 2). This was followed by improvements in his
HbA1c, serum insulin, and eosinophil levels; therefore, we
Table 1 Laboratory data on admission
Parameter Result (normal range) Unit Parameter Result (normal range) Unit
WBC 5400 (2800–8800) /μL γGTP 32 (10–47) IU/L
Neutrophil 60 (32–79) % Ch-E 378 (214–466) IU/L
Eosinophil 15 (0–6) % T-Bil 0.9 (0.2–1.2) mg/dL
Lymphocyte 16 (18–59) % Na 138 (138–146) mEq/L
Monocyte 7(0–8) % K 4.9 (3.6–4.9) mEq/L
Basophil 2(0–2) % Cl 99 (99–109) mEq/L
RBC 406×104 (366–478) /μL BUN 19 (8–22) mg/dL
Hb 13.0 (11.6–14) g/dL Cre 1.0 (0.4–0.7) mg/dL
Hct 38.0 (34.1–41.7) % UA 4.7 (2.3–7) mg/dL
Plt 15.2×104 (14.7–34.1) /μL CK 209 (62–287) IU/L
AMY 46 (42–132) IU/L
TP 7.2 (6.7–8.3) g/dL CRP 0.62 (0–0.3) mg/dL
Alb 3.6 (3.9–4.9) g/dL TC 149 (150–219) mg/dL
AST 33 (13–33) IU/L TG 70 (30–150) mg/dL
ALT 28 (6–27) IU/L HDL-C 50 (49–74) mg/dL
FPG 346 (70–109) mg/dL ANA Negative (<40×)
F-INS 9774 (5–10) μIU/mL CH50 <12 (25-48) CH50/mL
F-CPR 4.9 (0.6–2.1) ng/mL IgG 1697 (870–1700) mg/dL
HbA1c 12.3 (4.7–6.2) % Anti-SS-A antibody Negative
Glycoalbumin 48.3 (12.4–16.3) % Anti-SS-B antibody Negative
GAD antibody 0.3 (0–5.0) U/mL Anti-ds-DNA antibody Negative IU/mL
Human IgE 5.57 (0–0.34) U/mL RF <3 (<15) IU/mL
IgG-anti-insulin antibodies 14.5 (<0.3) %
Anti-insulin receptor antibodies Positive Urine test
ACTH 11.6 (7.2–63.3) pg/mL U-Glucose (4+)
Cortisol 17.9 (6.2–19.4) μg/dL U-Protein Negative
TSH 1.747 (0.5–5.0) μIU/mL U-Blood Negative
FT4 2.11 (0.9–1.7) ng/dL U-Ketone Negative
ACTH adrenocorticotropic hormone, Alb albumin, ALT alanine aminotransferase, AMY amylase, ANA anti-nuclear antibody, Anti-ds-DNA anti-double-stranded DNA,
anti-SS-A anti-Sjögren’s syndrome A, anti-SS-B anti-Sjögren’s syndrome B, AST aspartate aminotransferase, BUN blood urea nitrogen, Ch-E cholinesterase, CK
creatine, Cl chloride, Cre creatinine, CRP C-reactive protein, F-CPR fasting C-peptide, F-INS fasting insulin, FPG fasting plasma glucose, FT4 free thyroxine, GAD g
lutamic acid decarboxylase, γ-GTP γ-glutamyl transpeptidase, Hb hemoglobin, HbA1c glycated hemoglobin, Hct hematocrit, HDL-C high density lipoprotein
cholesterol, IgE immunoglobulin E, IgG immunoglobulin G, K potassium, Na sodium, Plt platelets, RBC red blood cells, RF rheumatoid factor, T-Bil total bilirubin,
TC total cholesterol, TG triglyceride, TP total protein, TSH thyroid-stimulating hormone, UA uric acid, WBC white blood cells
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decided to completely discontinue the insulin glargine after
3 months of the liraglutide treatment. On his new regimen
of 0.9 mg/day liraglutide in combination with oral antidia-
betic agents, his HbA1c level was maintained at approxi-
mately 7.0 %. The induration had almost completely
disappeared 1 month after the insulin injections were dis-
continued. In addition, his body weight decreased by 1.7 kg
after 2 months of liraglutide treatment. Table 3 indicates
his diabetes-related medical history.
Supplemental investigation by Scatchard analysis
We also elucidated the changes in the characteristics of
anti-insulin IgG antibodies before and after treatment
with liraglutide. Scatchard analysis of the anti-insulin
IgG antibodies in our case indicated that there was a
high binding capacity and a low affinity constant for the
high affinity sites before liraglutide therapy (Fig. 3). After
1 year of treatment with liraglutide, the Scatchard plot
indicated that the binding capacity decreased and the af-
finity constant for high affinity sites increased (Fig. 3).
Of interest, the anti-insulin receptor antibodies had
completely disappeared within 1 year after the injection
of liraglutide.
Discussion
There are two important aspects to this case. First, we
provide a rare description of insulin allergy associated
with hypereosinophilia, anti-insulin IgG antibodies, and
anti-insulin receptor antibodies in a patient with type 2
diabetes. Second, the marked efficacy of liraglutide sug-
gests that it is useful in all patients with type 2 diabetes.
In our case, we believed that our patient’s insulin
allergy was predominantly a type 1 immediate reaction
based on the fact that insulin lispro induced wheals,
itching, and redness immediately after injection. Insulin
allergy is typically classified into the following: type 1,
which is local and immediate; type 3, which is related to
autoimmune disease; and type 4, which is a delayed-type
reaction. Symptoms typically manifest within 15 minutes
after insulin injection in type 1 reactions, approximately
6 hours after type 3 reactions, and 8 to 24 hours after
type 4 reactions [2]. In our case, we confirmed that insu-
lin lispro induced immediate symptoms but could not
detect whether insulin aspart, glulisine, or glargine in-
duced those reactions.
We did not perform either a skin prick test or an intra-
dermal reaction test because of his past history of ana-
phylaxis. Out of concern for his safety, we substituted this
with a non-invasive drug-induced lymphocyte stimulation
test, which is normally considered best suited for delayed
(type 4) reactions. Although this test was only positive for
insulin glulisine, false-negatives have been detected in
some cases, and we considered that insulin glargine was
also associated with delayed-type allergy. This was because
insulin glargine induced occasional induration and be-
cause its discontinuation resulted in improvement of both
his induration and hypereosinophilia.
Based on the combination of these results, we con-
cluded that our patient probably had a delayed-type
allergic reaction that was complicated with a predom-
inant immediate-type allergic reaction. Unfortunately,
we did not obtain the list of additives in either the lis-
pro or glargine, which could have been important given
his history of protamine anaphylaxis. Further investiga-
tion of the cause of the allergic reactions could not be
performed (for example, to other insulin preparations,
including human neutral protamine Hagedorn, or the
additives in the insulin types).
Previous reports of type 1 and type 4 allergic reac-
tions to insulin indicate that hypereosinophilia does
not necessarily occur. Therefore, the increase of
eosinophilia in both local pathological findings and sys-
temic peripheral blood is characteristic of this case. In
general, although numerous eosinophils tend to be
detected in local inflammation, such as allergy and
parasitic infection, the complete role of eosinophils has
not been elucidated [10]. For example, although hyper-
eosinophilia has been observed in invasive parasitic
infection, it has recently been reported to be partially
defensive in vivo during such an infection [10]. In clin-
ical cases of hypereosinophilia, clinicians must quickly
and accurately diagnose the cause [11]. Potential causes
in the differential diagnosis of this case included
adrenal crisis, parasitic infection, and blood disease,
but there was no evidence in support of these diagno-
ses. In addition, because hypereosinophilia simultan-
eously occurred with the observed clinical course of
insulin allergy, we considered insulin allergy the more
likely cause. This was consistent with the report by
Nagai et al., who reported a case of immediate-type
allergy against human insulin associated with marked
eosinophilia in a patient with type 2 diabetes [12]. In that
case, there was also the possibility of hypereosinophilia-
induced renal dysfunction. Although there was no evi-
dence of organ damage in this case, clinicians should
remain vigilant for hypereosinophilic syndrome [11, 13]
and be prepared to initiate appropriate therapy. Currently,
Table 2 An evaluation of the patient’s insulin secretion ability
(a) Glucagon stimulation test
Time (minutes) 0 6
PG (pg/mL) 112 122
CP (ng/mL) 3.2 3.6
(b) Urinary C-peptide excretion
Day 18 (after admission) Day 19 Normal range
42.8 μg/day 51.5 μg/day (40–100)
CP C-peptide, PG plasma glucose
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Fig. 2 Clinical course. A diagrammatic representation of the treatment and clinical course of a 70-year-old man with insulin allergy. He presented
5 months before his admission with wheals, redness, and itching immediately after insulin lispro injection that progressed to an area of indur-
ation. A skin biopsy and blood tests confirmed an allergy, and after trialing different insulin regimens, we eventually introduced 0.3 mg liraglutide,
discontinued the short-acting insulin, and added glimepiride and metformin. However, induration intermittently occurred after insulin glargine
injections, so we eventually cross-tapered him off glargine and onto a liraglutide dose of 0.9 mg. Thereafter, his glycated hemoglobin, insulin, and
eosinophil levels gradually improved. Eo eosinophil count, HbA1c glycated hemoglobin, INS insulin dose
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treatment options for insulin allergy include switching to
another insulin device [2], steroid therapy [2], continuous
subcutaneous insulin infusion therapy [14], hyposensitiza-
tion therapy [15], pancreas transplantation [16], and anti-
IgE therapy [17]. However, reports on the treatment of
insulin allergy with hypereosinophilia are limited, and new
options are needed. Therefore, we consider that liraglutide
might be a breakthrough agent in the treatment of insulin
allergy with hypereosinophilia in patients with type 2 dia-
betes. Indeed, a Medline search indicated that at the time
of writing, we are the first to report the beneficial effects
of liraglutide in this setting.
Treatment with liraglutide requires the residual ability
to secrete insulin, but we do not know the appropriate
range of insulin secretion that is necessary. Previously,
Kozawa et al. reported that the cut-off value for predicting
the efficacy of liraglutide was 1.1 for the C-peptide index,
which was defined as (fasting C-peptide/glucose)×100,
and 1.5 ng/mL for fasting C-peptide [18]. This index was
also shown to be a predictive marker for the beta-cell area
of the human pancreas [18, 19]. Using a glucagon stimula-
tion test, Usui et al. reported that a ΔC-peptide value of
1.34 ng/mL was a useful cut-off point for switching from
insulin to liraglutide without developing hyperglycemia
[20]. In this case, although the fasting C-peptide level was
high, the ΔC-peptide in the glucagon stimulation test had
a low value. Therefore, liraglutide alone could not inhibit
postprandial hyperglycemia, and the antidiabetic drugs
glimepiride, metformin, and voglibose were combined to
achieve complete control. Moreover, the additional bene-
fits of liraglutide include the prevention of body weight
gain due to its appetite-suppressing and gastrointestinal
peristaltic movement-suppressing effects. Liraglutide and
other GLP-1 analogs have been reported to decrease body
weight [21, 22]. In our case, our patient’s body weight de-
creased by only 1.7 kg, but we could not administer lira-
glutide at a dose of more than 0.9 mg/day. Worldwide,
liraglutide is administered at a maximum dose of 1.8 mg/
day; however, Japan has approved that liraglutide is
administered at a maximum dose of only 0.9 mg/day.
In our case, it is possible that both the insulin allergy
and the presence of anti-insulin IgG antibodies themselves
aggravated our patient’s glycemic control. Therefore, we
tested his human leukocyte antigen-antigen D related
(HLA-DR) type based on the report by Uchigata et al. that
insulin autoimmune syndromes are strongly associated
with HLA-DR4 [23]. We showed that his HLA-DR types
were DR-9 and DR-15 and not DR-4; thus, we did not con-
sider HLA-DR to be a potential causative factor for produ-
cing anti-insulin IgG antibodies. Instead, we concluded
that the anti-insulin IgG antibodies resulted from the
exogenous insulin injection; thus, we used liraglutide with-
out insulin to decrease the amount of anti-insulin IgG
antibodies and to avoid further production.
Moreover, Scatchard analysis of the anti-insulin IgG
antibodies in our patient indicated that there was a high
binding capacity and a low affinity constant for high
affinity sites. At high affinity sites, Eguchi reported two
important patterns of Scatchard analysis of anti-insulin IgG
antibodies: (1) high (11.5 to 53.2) binding capacity (10−8 M)
and low (0.04 to 0.21) affinity constant (108 M−1) in insulin
autoimmune syndrome; and (2) low (0.12 to 1.1) binding
capacity (10−8 M) and high (1.45 to 7.11) affinity constant
(108 M−1) in patients with diabetes requiring insulin ther-
apy [24]. Therefore, the binding capacity and low affinity
constant for high affinity sites are clinically important. Our
patient had extremely high binding capacity and a low
affinity constant compared with previous reports. In par-
ticular, his extremely high binding capacity was consistent
with his high serum insulin levels.
After insulin therapy was discontinued and liraglutide
was started, the characteristics of his anti-insulin IgG anti-
bodies changed. Specifically, there was a notable decrease
in the binding capacity and an increase in the affinity con-
stant for high affinity sites (Fig. 3c). Hara et al. have
reported that antibody-mediated insulin resistance was
treated by ceasing insulin administration [25], whereas
Tamura et al. reported that liraglutide ameliorated the
anti-insulin IgG antibodies in a woman with type 2 dia-
betes receiving hemodialysis [26]. In our case, it remains
unclear how liraglutide might have affected our patient’s
anti-insulin IgG antibodies; however, a recent report has
suggested that GLP-1 receptor agonists interact with the
immune system. In fact, Hadjiyanni et al. reported that
GLP-1 receptor signaling selectively regulated murine
lymphocyte proliferation and maintained peripheral regu-
latory T cells in vivo [27]. In humans, the effects of GLP-1
receptor agonists have been investigated in patients with
psoriasis [28], but the detailed mechanism of action is
unclear. Further reports are needed to improve our under-
standing of these agents.
Anti-insulin IgG antibodies have often been reported
to induce hypoglycemia [8, 21, 23, 24]. Unfortunately,
we could not measure serum free insulin levels directly
Table 3 Timeline
Time Diabetes-related medical history
1980s Onset of type 2 diabetes mellitus
2009 Coronary artery bypass grafting was conducted,
anaphylaxis induced by intravenous protamine
sulfate administration
May 2011 Onset of allergy
July 2011 A skin biopsy and blood tests confirmed an allergy
24 October 2011 Admission to our hospital
14 December 2011 Liraglutide was additionally started
21 March 2012 Insulin discontinued
April 2012 The symptoms of insulin allergy almost
disappeared
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and do not know whether the anti-insulin receptor anti-
bodies really affected glucose metabolism. Although Kim
et al. reported that anti-insulin receptor antibodies often
coexist with anti-insulin IgG antibodies in Korean pa-
tients with insulin autoimmune syndrome [29], the clin-
ical significance of this finding has been not determined.
Acquired anti-insulin receptor antibodies induce severe
insulin resistance, called “type B insulin resistance,”
which was first reported in 1976 [30]. However, we
found no other symptoms or complications of type B
insulin resistance, such as acanthosis nigricans or auto-
immune disease (Table 1). In addition, the total insulin
dose was smaller than that reported in previous studies
on type B insulin resistance [9, 30]. Therefore, we con-
sidered the possibility that the presence of anti-insulin
receptor antibodies is a false positive in this case. It is
also possible that the method of measurement led to a
false positive result for anti-insulin receptor antibodies
because we used the insulin binding inhibition method
[31]. Perhaps the high insulin levels and high anti-
insulin IgG antibodies levels had some unknown influ-
ence on the measured values.
Conclusions
In conclusion, our case suggests that liraglutide is a
useful treatment for insulin allergy associated with
Fig. 3 Scatchard plot analysis showing changes in the characteristics of anti-insulin immunoglobulin G antibodies before and after treatment with
liraglutide. a The Scatchard plot analysis before the treatment of liraglutide. The binding capacity (10−8 M) of 882 (R1) and affinity constant (10
8 M
−1) of 0.000582 (K1) for high affinity sites and the binding capacity (10
−8 M) of 4830 (R2) and affinity constant (10
8 M−1) of 0.0000190 (K2) for low
affinity sites are shown. b The Scatchard plot analysis approximately 1 year after starting liraglutide. The binding capacity (10−8 M) of 70.6 (R1) and
affinity constant (108 M−1) of 0.00203 (K1) for high affinity sites and the binding capacity (10
−8 M) of 298 (R2) and affinity constant (10
8 M−1) of
0.0000704 (K2) for low affinity sites are shown. c It is notable, particularly for high affinity sites, that the binding capacity (10
−8 M) has changed
from 882 to 70.6 (R1), and that the affinity constant (10
8 M−1) has changed from 0.000582 to 0.00203 (K1). Therefore, liraglutide appeared to induce
a decrease in the binding capacity and an increase in the affinity constant for high affinity sites of anti-insulin immunoglobulin G antibodies
Hirai et al. Journal of Medical Case Reports  (2016) 10:202 Page 7 of 8
hypereosinophilia and anti-insulin IgG antibodies in
patients with type 2 diabetes. However, similar case
reports are limited, and further reports are clearly needed.
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